舒泰神(300204) - 2024 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2024 was ¥78,598,099.03, a decrease of 25.21% compared to the same period last year[2] - The net profit attributable to shareholders for Q3 2024 was -¥5,941,948.01, an increase of 81.16% year-on-year[2] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥6,928,798.57, reflecting a 79.50% increase compared to the previous year[2] - For the period from January to September 2024, the company achieved operating revenue of 260.99 million yuan, a year-on-year decrease of 4.91%[14] - The total operating revenue for Q3 2024 was approximately ¥260.99 million, a decrease from ¥274.45 million in the same period last year, representing a decline of about 4.8%[24] - The total profit for Q3 2024 was approximately -¥9.36 million, compared to -¥183.25 million in the same period last year, showing a significant reduction in losses[24] Cash Flow - The cash flow from operating activities for the year-to-date period was -¥24,733,298.84, showing an improvement of 82.54% year-on-year[3] - The net cash flow from operating activities for Q3 2024 was -24,733,298.84, an improvement from -141,631,470.31 in Q3 2023[26] - Total cash inflow from operating activities was 272,830,029.28, compared to 366,969,639.33 in the previous year, indicating a decrease of approximately 25.6%[26] - Cash outflow from operating activities totaled 297,563,328.12, down from 508,601,109.64, reflecting a reduction of about 41.4%[26] - The net cash flow from investing activities was -5,002,474.83, a significant decline from 16,652,507.23 in Q3 2023[26] - Cash inflow from investing activities was 25,786,739.64, compared to 39,654,067.52 in the same period last year, representing a decrease of approximately 35%[26] - Cash outflow from investing activities increased to 30,789,214.47 from 23,001,560.29, marking an increase of about 33.9%[26] - The net cash flow from financing activities was -13,014,792.03, a decrease from 56,272,743.03 in Q3 2023[27] - Total cash inflow from financing activities was 16,325,860.00, down from 74,805,175.56, indicating a decline of approximately 78.1%[27] - The ending cash and cash equivalents balance was 42,731,525.34, down from 196,557,453.09 in the previous year, reflecting a decrease of about 78.3%[27] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,284,119,316.33, a decrease of 3.61% from the end of the previous year[3] - The company's total assets decreased to ¥1,284,119,316.33 from ¥1,332,220,277.68, a decline of 3.6%[22] - The company's equity attributable to shareholders increased to ¥1,032,899,973.17, reflecting a growth of 1.20% from the previous year[3] - The company's total liabilities decreased significantly, with short-term borrowings reduced to ¥0 from ¥28,826,188.29 at the end of the previous year[6] - Total liabilities decreased to ¥251,219,343.16 from ¥311,552,399.39, a reduction of 19.4%[22] Research and Development - Research and development expenses decreased by ¥173,291,483.18, a reduction of 69.05% compared to the same period last year[7] - The cumulative R&D expenses for the same period were 77.69 million yuan, down 69.05% compared to the previous year[14] - Research and development expenses for Q3 2024 were approximately ¥77.69 million, a substantial decrease of 69% compared to ¥250.98 million in the previous year[24] Other Income and Expenses - The company reported a significant increase in other income, which rose by ¥1,276,603.62, or 38.12%, primarily due to government subsidies recognized during the period[7] - Tax refunds received increased by CNY 1,263,935.03, a growth of 254.59% compared to the same period last year, mainly due to the subsidiary's tax refund for retained tax credits[8] - Cash received from other operating activities decreased by CNY 13,300,826.22, a decline of 71.70%, primarily due to reduced cash flow from operating activities[8] - Cash paid for purchasing goods and services decreased by CNY 38,053,876.97, a reduction of 68.56%, mainly due to decreased purchases of R&D reagents and consumables[8] - Cash paid for other operating activities decreased by CNY 131,372,547.06, a decrease of 48.20%, primarily due to reduced R&D payments[8] - The company experienced a decrease in sales expenses, which were approximately ¥114.57 million, down from ¥123.03 million year-over-year, indicating a reduction of about 6.0%[24] - The financial expenses for Q3 2024 showed a notable improvement, with a net financial income of approximately -¥39.65 thousand compared to -¥1.26 million in the previous year[24] Clinical Trials and Approvals - The company received clinical trial approval for STSP-0902 eye drops for the treatment of neurotrophic keratitis on July 9, 2024[15] - The Phase I clinical trial of STSA-1301 subcutaneous injection for primary immune thrombocytopenia (ITP) showed good safety and tolerability in healthy subjects[16] - The first subject was dosed in the Phase I clinical trial of STSP-0902 injection for the treatment of oligospermia on August 15, 2024[16] Corporate Actions - A total of 2.3 million USD in interest-free loans was provided by the controlling shareholder to support the company's subsidiary in Hong Kong[15] - The company announced the absorption merger of its wholly-owned subsidiary, Beijing Shutai Shen Pharmaceutical Technology Co., Ltd., to optimize management structure and improve operational efficiency[15] - The company completed the business registration change for its subsidiary Sichuan Shutai Shen Pharmaceutical Co., Ltd. due to business development needs[17] - The controlling shareholder transferred 24,366,400 shares, representing 5.10% of the company's total share capital, to an associated party[17] - The company received the drug registration certificate for Compound Polyethylene Glycol (3350) Electrolyte Vitamin C Powder on October 9, 2024[19]